Genmab — M&A Activity 2012

Dec 5, 2012

Company Announcement

• DuoBody® research collaboration with Kyowa Hakko Kirin
• Genmab’s fourth DuoBody technology collaboration

Copenhagen, Denmark; December 5, 2012 – Genmab A/S (OMX: GEN) announced today a
research collaboration with Kyowa Hakko Kirin Co., Ltd. to create bispecific
antibodies using Genmab’s DuoBody technology. If successful, the parties may
decide to enter into a license agreement to develop a new DuoBody product.

“We have made excellent progress in partnering our innovative DuoBody
technology platform, with the Kyowa Hakko Kirin agreement marking our fourth
DuoBody platform collaboration within the past year. We believe this keen level
of interest on the part of top tier pharmaceutical companies clearly
illustrates the promise of bispecific antibodies created with the DuoBody
platform, and also demonstrates the technology’s compatibility with a range of
antibody-platforms,” said Jan van de Winkel, Ph.D., Chief Executive Officer of
Genmab.

The financial terms of the agreement have not been disclosed. This agreement
will not have a material impact on Genmab’s 2012 financial guidance.

About the DuoBody Platform
The DuoBody platform is an innovative platform for the discovery and
development of bispecific antibodies that may improve antibody therapy of
cancer, autoimmune, infectious and central nervous system disease. Bispecific
antibodies bind to two different epitopes either on the same, or on different
targets (also known as dual-targeting) which may improve the antibodies’
specificity and efficacy in inactivating the disease targets. DuoBody molecules
are unique in combining the benefits of bispecificity with the strengths of
conventional antibodies which allows DuoBody molecules to be administered and
dosed as other antibody therapeutics. Genmab’s DuoBody platform generates
bispecific antibodies via a fast and broadly applicable process which is easily
performed at standard bench, as well as commercial, manufacturing scale.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody® and UniBody®
are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Company Announcement no. 32
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark